Is this you? Create Your Porfile
Avatar

J. Fan

Boehringer Ingelheim

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where J. Fan is active.

Explore More

Publication

Featured researches published by J. Fan.

Annals of Oncology | 2016

Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)

L. Paz-Ares; E.H. Tan; L. Zhang; Vera Hirsh; Kenneth J. O'Byrne; Michael Boyer; J.C-H. Yang; T. Mok; Ki Hyeong Lee; Shun Lu; Yuankai Shi; S. Kim; Janessa Laskin; D-W. Kim; Scott A. Laurie; K. Kölbeck; J. Fan; N. Dodd; A. Märten; K. Park

Journal of Thoracic Oncology | 2017

P3.01-036 A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis

Yi-Long Wu; Hai-Yan Tu; Jifeng Feng; M. Shi; J. Zhao; Yan Wang; Jianhua Chang; Jialei Wang; Ying Cheng; J. Zhu; E. Tan; K. Li; Y. Zhang; Victor Ho Fun Lee; Cheng-Ta Yang; Wei-Fang Su; C.L. Lam; B. Srinivasa; S. Rajappa; Ching Liang Ho; K.C. Lam; Y. Hu; S.A. Bondarde; Xiaoqing Liu; J. Fan; D. Kuo; K. Pang; C. Zhou

Annals of Oncology | 2017

93PDAfatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)

J. Corral; K. Park; J.C-H. Yang; T. Mok; E-H. Tan; Kenneth J. O'Byrne; Vera Hirsh; Michael Boyer; J. Fan; L. Zhang

Journal of Thoracic Oncology | 2017

P3.01-026 Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC

Martin Schuler; James Chih-Hsin Yang; Lecia V. Sequist; Y. Wu; C. Zhou; Sarayut Lucien Geater; T. Mok; Eng-Huat Tan; Chunhong Hu; Nobuyuki Yamamoto; Jifeng Feng; Kenneth J. O’Byrne; Shunyuan Lu; Vera Hirsh; Y. Huang; S. Ellis; C. Samuelsen; A. Märten; J. Fan; K. Park; Luis Paz-Ares

Journal of Thoracic Oncology | 2017

OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7

Keunchil Park; Eng Huat Tan; Li Zhang; Vera Hirsh; Kenneth J. O'Byrne; Michael Boyer; James Chih-Hsin Yang; Tony Mok; Ki Hyeong Lee; Shun Lu; Yuankai Shi; Sang-We Kim; Janessa Laskin; Dong-Wan Kim; Scott A. Laurie; Karl Kölbeck; J. Fan; Nigel Dodd; A. Märten; Luis Paz-Ares

Annals of Oncology | 2017

100PAfatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment

J.C-H. Yang; Luis Paz-Ares; E-H. Tan; Kenneth J. O'Byrne; L. Zhang; Michael Boyer; T. Mok; Vera Hirsh; J. Fan; K. Park

Faculty of Health; Institute of Health and Biomedical Innovation | 2016

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial

Luis Paz-Ares; E.H. Tan; Kenneth J. O'Byrne; L. Zhang; Vera Hirsh; Michael Boyer; J.C-H. Yang; T. Mok; K.H. Lee; Shun Lu; Yuankai Shi; D. H. Lee; Janessa Laskin; D-W. Kim; Scott A. Laurie; Karl Kölbeck; J. Fan; N. Dodd; A. Märten; K. Park

European Respiratory Journal | 2016

Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: LUX-Lung 7

Vera Hirsh; Keunchil Park; Eng-Huat Tan; Li Zhang; Kenneth J. O'Byrne; Michael Boyer; James Chih-Hsin Yang; Tony Mok; J. Fan; Dan Massey; Luis Paz-Ares

Annals of Oncology | 2016

Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial

Martin Schuler; E.H. Tan; Kenneth J. O'Byrne; L. Zhang; Michael Boyer; T. Mok; Vera Hirsh; J.C-H. Yang; K H Lee; Shun Lu; Yuankai Shi; S. Kim; Janessa Laskin; D-W. Kim; C. Dubos Arvis; Karl Kölbeck; Dan Massey; J. Fan; Luis Paz-Ares; K. Park

Annals of Oncology | 2016

440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)

K. Park; E.H. Tan; L. Zhang; Vera Hirsh; Kenneth J. O'Byrne; Michael Boyer; J.C-H. Yang; T. Mok; K H Lee; Shun Lu; Yuankai Shi; S. Kim; Janessa Laskin; D. Kim; Scott A. Laurie; K. Kölbeck; J. Fan; N. Dodd; A. Märten; L. Paz-Ares

Explore More

Collaboration

Dive into the J. Fan's collaboration.

Top Co-Authors
Avatar

Vera Hirsh

McGill University

View shared research outputs
Top Co-Authors
Avatar

Kenneth J. O'Byrne

Queensland University of Technology

View shared research outputs
Top Co-Authors
Avatar

Michael Boyer

University of Sydney

View shared research outputs
Top Co-Authors
Avatar

T. Mok

The Chinese University of Hong Kong

View shared research outputs
Top Co-Authors
Avatar

K. Park

Samsung Medical Center

View shared research outputs
Top Co-Authors
Avatar

L. Zhang

Sun Yat-sen University

View shared research outputs
Top Co-Authors
Avatar

Luis Paz-Ares

Complutense University of Madrid

View shared research outputs
Top Co-Authors
Avatar

Shun Lu

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors
Avatar

Yuankai Shi

Peking Union Medical College

View shared research outputs
Top Co-Authors
Avatar

J.C-H. Yang

National Taiwan University

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge